Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

Fabio P.S. Santos, Hagop Kantarjian, Carmen Fava, Susan O'Brien, Guillermo Garcia-Manero, Farhad Ravandi, William Wierda, Deborah Thomas, Jianquin Shan, Jorge Cortes

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Fingerprint

Dive into the research topics of 'Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia'. Together they form a unique fingerprint.

Medicine & Life Sciences